MENU
+Compare
JDOC
ETF ticker: NASDAQ
AS OF
Jul 22 closing price
Price
$50.18
Change
+$0.71 (+1.44%)
Net Assets
7.42M

JDOC stock forecast, quote, news & analysis

The investment seeks to provide long-term capital appreciation... Show more

Category: #Health
JDOC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for JDOC with price predictions
Jul 22, 2025

JDOC sees MACD Histogram crosses below signal line

JDOC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 21, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 15 instances where the indicator turned negative. In of the 15 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for JDOC moved out of overbought territory on July 16, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JDOC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JDOC broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on July 22, 2025. You may want to consider a long position or call options on JDOC as a result. In of 25 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

JDOC moved above its 50-day moving average on July 22, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for JDOC crossed bullishly above the 50-day moving average on July 11, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JDOC advanced for three days, in of 89 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 85 cases where JDOC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Bristol-Myers Squibb Co (NYSE:BMY).

Industry description

The investment seeks to provide long-term capital appreciation. The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.

Market Cap

The average market capitalization across the JPMorgan Healthcare Leaders ETF ETF is 80.26B. The market cap for tickers in the group ranges from 1.24B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is ROG at 1.24B.

High and low price notable news

The average weekly price growth across all stocks in the JPMorgan Healthcare Leaders ETF ETF was 19%. For the same ETF, the average monthly price growth was 22%, and the average quarterly price growth was 75%. CTEC experienced the highest price growth at 6%, while SRPT experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the JPMorgan Healthcare Leaders ETF ETF was 14%. For the same stocks of the ETF, the average monthly volume growth was -32% and the average quarterly volume growth was 25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 68
Price Growth Rating: 57
SMR Rating: 65
Profit Risk Rating: 67
Seasonality Score: 9 (-100 ... +100)
View a ticker or compare two or three
JDOC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
J.P. Morgan Exchange-Traded Fund Trust270 Park AvenueNew York
Phone
(800) 480-4111
Web
N/A